Drug Type Small molecule drug |
Synonyms BOL-303213X, CEP 11981, ESK 981 + [3] |
Target |
Action antagonists |
Mechanism Tie-2 antagonists(TEK receptor tyrosine kinase antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC28H27N7O |
InChIKeyAEULIVPVIDOLIN-UHFFFAOYSA-N |
CAS Registry856691-93-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenosquamous Carcinoma | Phase 2 | United States | 19 Apr 2024 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | United States | 19 Apr 2024 | |
Neuroendocrine neoplasm of gastrointestinal tract | Phase 2 | United States | 19 Apr 2024 | |
Neuroendocrine tumor of pancreas | Phase 2 | United States | 19 Apr 2024 | |
Pancreatic adenocarcinoma | Phase 2 | United States | 19 Apr 2024 | |
Prostate Neuroendocrine Carcinoma | Phase 2 | United States | 19 Apr 2024 | |
Well Differentiated Pancreatic Endocrine Tumor | Phase 2 | United States | 19 Apr 2024 | |
Metastatic Renal Cell Carcinoma | Phase 2 | United States | 11 Apr 2019 | |
Prostatic Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - |
Phase 2 | Metastatic castration-resistant prostate cancer prostate-specific antigen | AR amplification | 10 | dlhrcfogdy(wlhjudamny) = khcafcskdp ecrdebqtdk (bwculmcoln, 1.8 - 22.4) View more | Negative | 06 Nov 2024 | ||
Phase 2 | Castration-Resistant Prostatic Cancer androgen receptor-positive (AR +) | 13 | mavlmlzprg(enokfwypox) = hcejdduuuz jahfhpbeav (qkitnjnnqq, 0.4 - 33.3) View more | Negative | 03 Sep 2024 | ||
Phase 2 | 13 | dommwjqtby = iclqxmjitp cdjrvmcfla (odwdtezpkc, pmqxwkpcna - lwqhoptjja) View more | - | 14 Jul 2023 |